pharm t1 cardiac indications & outcomes

Indications: HTN, angina pectoris & vasospastic (prinzmetal's angina). Supraventricular tachyarrhytmias and rapid ventricular rates in atrial flutter or fibrillation

Desired Outcomes:
-decrease in BP
-decrease in freq & severity of anginal attacks
-decrease in need for nitrate therapy
-increase in activity tolerance & sense of well-being
-supression and prevention of tachyarrhythmia

Indications: HTN, angina pectoris, prevention of MI and decreased mortality in pts w/recent MI. Mgmt of stable, symptomatic (class II or III) HF due to ischemic, hypertensive, or cardiomyopathic origin (may be used with ACE inhibitors, diuretics, and/or digoxin.)

Unlabeled use: ventricular arrhythmias/tachycardia. Migraine prophylaxis. Tremors. Aggressive behavior. Drug-induced akathasia. Anxiety.

Desired Outcomes:
- Decresed BP
-Reduction in freq. of anginal attacks
-increase in activity tolerance
-Prevention of MI

Indications: Life threatening ventricular arrythmias unresponsive to less toxic agents.

Unlabeled Use:
PO- mgmt of SVTs
IV-part of ACLS and PALS guidelines for mgmt of vFib/pulseless ventricular tachycardia after CPR and defibrillation have failed. Also for other life-threatening tachyarrhythmias.

Desired Outcomes:
-cessation of life-threatening ventricular arrhythmias. Adverse effects may take up to 4 months to resolve.

Indications: edema due to CHF, hepatic or renal disease. HTN

Desired Outcomes:
-decrease in edema
-decrease in abdominal girth & weight
-decrease in BP
-increase in urinary output

Indications: Adjuct to standard measures to improve: Blood pressure, cardiac output, urine output in treatment of shock unresponsive to fluid replacement. Increase renal perfusion (low doses).

Desired Outcomes:
-Increase in BP
-Increase in peripheral circulation
-Increase in urine output

Indications:
SubQ, IV, Inhaln: Mgmt of reversible airway disease due to asthma or COPD.
SubQ, IM, IV: mgmt of severe allergic reactions
IV, Intracardia, Intratracheal, Intraosseous (part of ACLS and PALS guidelines): mgmt of cardiac arrest (unlabeled).
Inhaln: mgmt of upper airway obstruction and croup (racemic epinephrine).
Local/spinal: adjunc in the localization/prolongation of anesthesia.

Desired Outcomes:
-prevention or relief of bronchospasm
-increase in ease of breathing
-prevention of bronchospasm or reduction of frequency of acute asthma attacks in pts w/chronic asthma.
-Prevention of exercise-induced asthma
-reversal of s/s of anaphylaxis
-increase in cardiac rate and output, when used in cardaic resuscitation.
-Increase in BP, when used as vasopressor
-Localization of local anesthetic
-Decrease in sinus and nasal congestion